L-Deprenyl (selegiline) limits the repetitive firing of action potentials in rat hippocampal CA1 neurons via a dopaminergic mechanism

Brain Research

Volumn 753, Issue 1, 1997, Pages 27-35

  Huang, Chiung Chun ^a   Tsai, Jing Jane ^a   Hsu, Kuei Sen ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

dopamine; hippocampal slice; intracellular recording; L deprenyl; monoamine oxidase type B (MAO B) inhibitor; rat

Indexed keywords

8 BROMO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; SELEGILINE; SULPIRIDE;

ACTION POTENTIAL; ANIMAL CELL; ARTICLE; DOPAMINERGIC SYSTEM; HIPPOCAMPUS; HYPERPOLARIZATION; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ACTION POTENTIALS; ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; DOPAMINE; MALE; MEMBRANE POTENTIALS; MONOAMINE OXIDASE INHIBITORS; PARGYLINE; PYRAMIDAL CELLS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; SELEGILINE;

EID: 0030979442     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(96)01482-5     Document Type: Article

References (37)

1. Alger, B.E. and Nicoll, R.A., Epileptiform burst afterhyperpolarization: calcium-dependent potassium potential in hippocampal CA1 pyramidal cells, Science, 210 (1980) 1122-1124.
2. Arai, Y., Kinemuchi, H., Hamamichi, N., Satoh, N., Tadano, T. and Kisara, K., Inhibition of rat brain monoamine oxidase by some analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenyl-pyridinium ion, Neurosci. Lett., 66 (1986) 43-48.
3. Berretta, N., Berton, F., Bianchi, R., Capopna, M., Francesconi, W. and Brunelli, M., Effects of dopamine D-1 and D-2 dopaminergic agonists on the excitability of hippocampal CA1 pyramidal cells in guinea pig, Exp. Brain Res., 83 (1990) 124-130.
4. Dailey, J.W. and Jobe, P.C., Indices of noradrenergic function in the central nervous system of seizure-naive genetically epilepsy-prone rats, Epilepsia, 27 (1986) 665-670.
5. 3H]SCH 23390, Eur. J. Pharmacol., 108 (1985) 322-325.
6. Fowler, C.J., Oreland, L. and Callingham, B.A., The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J-508: their properties and applications, J. Pharm. Pharmacol., 33 (1981) 341-347.
7. Heinonen, E.H. and Lammintausta, R., A review of the pharmacology of selegiline, Acta Neurol. Scand., 84 (1991) 44-59.
8. Hotson, J.R. and Prince, D.A., A Ca-activated hyperpolarization follows repetitive firing in hippocampal neurons, J. Neurophysiol., 43 (1980) 409-419.
9. +) of N-methyl-D-aspartate-activated currents in rat hippocampal neurons, Neurosci. Lett., 189 (1995) 17-22.
10. Hsu, K.S., Characterization of dopamine receptors mediating inhibition of excitatory synaptic transmission in the rat hippocampal slice, J. Neurophysiol., 76 (1996) 1887-1895.
11. Hsu, K.S., Huang, C.C., Su, M.T. and Tsai, J.J., L-Deprenyl (selegiline) decreases excitatory synaptic transmission in the rat hippocampus via a dopaminergic mechanism, J. Pharmacol. Exp. Ther., 279 (1996) 740-747.
12. Knoll, J., The striatal dopamine dependency of life span in male rats. Longevity study with (-)-deprenyl, Mech. Aging Dev., 46 (1988) 237-262.
13. Knoll, J., The pharmacological profile of (-)-deprenyl (selegiline) and its relevance for humans: a personal view, Pharmacol. Toxicol., 70 (1992) 317-321.
14. 2 receptors in the rat hippocampal region, Neurosci. Lett., 126 (1991) 107-109.
15. Lancaster, B. and Nicoll, R.A., Properties of two calcium-activated hyperpolarizations in rat hippocampal neurones, J. Physiol., 389 (1987) 187-204.
16. Löscher, W. and Honack, D., Anticonvulsant and antiepileptogenic effect of L-deprenyl (selegiline) in the kindling model of epilepsy, J. Pharmacol. Exp. Ther., 274 (1995) 307-314.
17. Löscher, W. and Lehmann, H., L-Deprenyl (selegiline) exerts anti-convulsant effects against different seizure types in mice, J. Pharmacol. Exp. Ther., 211 (1996) 1410-1417.
18. Madison, D.V. and Nicoll, R.A., Control of repetitive discharge of rat pyramidal neurons in vitro, J. Physiol., 354 (1984) 319-331.
19. Mansour, A., Meador-Woodruff, J.H., Zhou, Q., Civelli, Q., Akil, H. and Watson, S.J., A comparsion of D1 receptor binding and mRNA in rat brain using receptor autoradiographic and in situ hybridization techniques, Neuroscience 46 (1992) 959-971.
20. Martini, E., Pataky, I., Szilagyi, K. and Venter, V., Breif information on an early phase II-study with deprenyl in demented patients, Pharmacopsychiatry, 20 (1987) 256-257.
21. Mclean, M.J. and Macdonald, R.L., Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing action potentials of mouse central neurons in cell culture, J. Pharmacol. Exp. Ther., 237 (1986) 1001-1011.
22. Mclean, M.J. and Macdonald, R.L., Carbamazepine and 10, 11-epoxycarbamazepine produce use- and voltage-dependent limitation of repidly firing action potentials of mouse central neurons in cell culture, J. Pharmacol. Exp. Ther., 238 (1986) 727-738.
23. 2 dopaminergic receptor mRNAs in rat brain, Neuropsychopharmacology, 5 (1991) 231-242.
24. O'Donnell, P. and Grace, A.A., Dopaminergic modulation of dye coupling between neurons in the core and shell regions of the nucleus accumbens, J. Neurosci., 13 (1993) 2456-2471.
25. Peacock, J.H. and Walker, C.R., Development of calcium action potentials in mouse hippocampal cell cultures, Dev. Brain Res., 8 (1983) 39-52.
26. 3H] SKF 38393, Eur. J. Pharmacol., 111 (1985) 145-146.
27. Scatton, B., Simon, H. and LE Moal, M. and Bischoff, S., Origin of dopaminergic innervation on the rat hippocampal formation, Neurosci. Lett., 18 (1980) 125-131.
28. Schlesinger, K., Boggan, W.Q. and Freedman, D.X., Genetics of audiogenic seizures. III. Time response relationships between drug administration and seizure susceptibility, Life Sci., 9 (1970) 721-729.
29. 1 like dopamine receptor, J. Neurochem., 45 (1985) 1601-1611.
30. 3H]leucine and horseradish peroxidase, Brain Res., 178 (1979) 17-40.
31. Storm, J.F., Action potential repolarization and a fast after-hyperpolarization in rat hippocampal pyramidal cells, J. Physiol., 385 (1987) 733-759.
32. Storm, J.F., An after-hyperpolarization of medium duration in rat hippocampal pyramidal cells, J. Physiol., 409 (1989) 171-190.
33. Suppes, T., Kriegstein, A.R. and Prince, D.A., The influence of dopamine on epileptiform burst activity in hippocampal pyramidal neurons, Brain Res., 326 (1985) 273-280.
34. Verney, C., Baulack, M., Berger, B., Alvarez, C., Vigny, A. and Helle, K., Morphological evidence for a dopaminergic terminal field in the hippocampal formation of young and adult rat, Neuroscience 14 (1985) 1039-1052.
35. Wessel, K. and Szelenyi, I., Selegiline-an overview of its role in the treatment of Parkinson's disease, Clin. Invest., 70 (1992) 459-462.
36. Yahr, M.D., Parkinson's disease: new approaches to diagnosis and treatment, Acta Neurol. Scand. Suppl. , 146 (1993) 22-25.
37. Yavich, L., Sirvio, J., Heinonen, E. and Riekkinen, P. The interaction of L-deprenyl and scopolamine on spatial learning/memory in rats, J. Neural Transm., 6 (1993) 189-197.